bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
200 hedge funds and large institutions have $3.01B invested in bluebird bio in 2016 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 64 increasing their positions, 60 reducing their positions, and 21 closing their positions.
114% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 21
58% more capital invested
Capital invested by funds: $1.9B → $3.01B (+$1.11B)
13% more funds holding
Funds holding: 177 → 200 (+23)
7% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 60
10% less call options, than puts
Call options by funds: $51.9M | Put options by funds: $58M
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$51.5M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$36.6M |
| 3 |
Millennium Management
New York
|
+$24.3M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$18.1M |
| 5 |
PC
Passport Capital
San Francisco,
California
|
+$16.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
-$31.6M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$29.7M |
| 3 |
RI
RTW Investments
New York
|
-$29.3M |
| 4 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$25.7M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$21.6M |
BLUE Hedge Fund Activity: Q3 2016 in Review
200 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q3 2016, worth a combined $3.01B — up 58% from $1.9B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new BLUE positions and 21 closed out — a net gain of 24 holders — while 64 added to existing stakes and 60 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $51.5M. The largest seller was OppenheimerFunds, cutting an estimated $31.6M.
- 200 institutional investors held bluebird bio (BLUE) as of Q3 2016, up from 177 in Q2 2016.
- Funds reported $3.01B of bluebird bio stock for Q3 2016, up 58% quarter-over-quarter.
- 45 funds opened new bluebird bio positions in Q3 2016 and 21 closed out, a net change of +24 holders.
- The largest bluebird bio buyer in Q3 2016 was T. Rowe Price Associates, an estimated $51.5M added.
- The largest bluebird bio seller in Q3 2016 was OppenheimerFunds, an estimated $31.6M sold.
Based on aggregated 13F filings for Q3 2016.